Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
Open Access
- 25 October 2023
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 37 (12) , 2346-2355
Abstract
In the absence of randomized controlled trials comparing tisagenlecleucel vs. standard of care (SOC) in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL), the objective was to compare the efficacy of tisagenlecleucel with historical controls from multiple disease registries using patient-level adjustment of the historical controls. The analysis is based on patient-level data of three tisagenlecleucel studies (ELIANA, ENSIGN and CCTL019B2001X) vs. three registries in Germany/Austria. Statistical analyses were fully pre-specified and propensity score weighting of the historical controls by fine stratification weights was used to adjust for relevant confounders identified by systematic literature review. Results showed high comparability of cohorts after adjustment with absolute SMD ≤ 0.1 for all pre-specified confounders and favorable outcomes for tisagenlecleucel compared to SOC for all examined endpoints. Hazard ratios for OS(Intention to treat)ITT,adjusted, EFS(Full analysis set)FAS,naïve and RFSFAS,naïve were 0.54 (95% CI: 0.41–0.71, p < 0.001), 0.67 (0.52–0.86, p = 0.001) and 0.77 (0.51–1.18, p = 0.233). The OSITT, adjusted, EFSFAS,naïve and RFSFAS,naive survival probability at 2 years was 59.49% for tisagenlecleucel vs. 36.16% for SOC population, 42.31% vs. 30.23% and 59.60% vs. 54.57%, respectively. Odds ratio for ORRITT,adjusted was 1.99 (1.33–2.97, p < 0.001). Results for OS and ORR were statistically significant after adjustment for confounders and provide evidence supporting a superiority of tisagenlecleucel in r/r ALL given the good comparability of cohorts after adjustment for confounders.Keywords
This publication has 17 references indexed in Scilit:
- Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic LeukemiaAdvances in Therapy, 2019
- Methods for Population-Adjusted Indirect Comparisons in Health Technology AppraisalMedical Decision Making, 2017
- Epidemiologie akuter Leukämien in Deutschland Epidemiology of acute leukemia in GermanyDer Onkologe, 2017
- Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in AdultsCurrent Oncology Reports, 2016
- Stem-Cell Transplantation in Children With Acute Lymphoblastic Leukemia: A Prospective International Multicenter Trial Comparing Sibling Donors With Matched Unrelated Donors—The ALL-SCT-BFM-2003 TrialJournal of Clinical Oncology, 2015
- Aktuelle Therapie der akuten lymphatischen Leukämie des ErwachsenenDie Innere Medizin, 2015
- Prognostic score–based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness researchJournal of Clinical Epidemiology, 2013
- How I treat relapsed childhood acute lymphoblastic leukemiaBlood, 2012
- Matching-Adjusted Indirect Comparisons: A New Tool for Timely Comparative Effectiveness ResearchValue in Health, 2012
- Adult acute lymphoblastic leukaemiaCritical Reviews in Oncology/Hematology, 2004